Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 26;15(37):30135-30145.
doi: 10.1039/d5ra03671b. eCollection 2025 Aug 22.

Regioselective Ru(ii)-catalyzed C-H alkenylation and annulation of indoles: a direct approach to fused lactone scaffolds

Affiliations

Regioselective Ru(ii)-catalyzed C-H alkenylation and annulation of indoles: a direct approach to fused lactone scaffolds

Jithender Rallabandi et al. RSC Adv. .

Abstract

In this work, we offer a method for selectively alkenylating C5-H and then annulating indole-4-carboxylic acid derivatives using ruthenium(ii) as a catalyst. Our approach facilitates the effective formation of fused lactone structures by employing a weakly coordinating carboxylic acid group at the C4 position as a guiding group. The reaction process starts with an alkenylation at the C5 position of the indole ring, followed by an intramolecular Michael addition to produce annulated lactones in high yields. This is the first report of ruthenium-catalyzed lactone synthesis at the C5 position of indoles via a carboxylic acid directing group. We anticipate that because of its simplicity, high regioselectivity, and use of readily available starting materials, this process will open up new options for constructing functionalized lactone scaffolds that could be immensely valuable in medical and pharmacological studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Fig. 1
Fig. 1. Pharmaceutically active compounds containing indole and lactone derivatives.
Scheme 1
Scheme 1. Comparison with previous works.
Scheme 2
Scheme 2. Scope of indole derivatives and acrylatesa,b. aReaction conditions: 1 (1.0 equiv.), 2 (1.1 equiv.), [RuCl2(p-cymene)]2 (2.5 mol%), Cu(OAc)2·H2O (1.5 equiv.), KOAc (0.5 equiv.), dioxane (0.2 M), 80 °C, 6 h. bIsolated yields; (Me = methyl, Et = ethyl, tBu-t-butyl, Bn = benzyl, Ph = phenyl).
Scheme 3
Scheme 3. C5-alkenyation–annulation of indole derivatives with various alkenes. aReaction conditions: 1 (1.0 equiv.), 2 (1.1 equiv.), [RuCl2(p-cymene)]2 (2.5 mol%), Cu(OAc)2·H2O (1.5 equiv.), KOAc (0.5 equiv.), dioxane (0.2 M), 80 °C, 6 h. bIsolated yields; (Me = methyl, Et = ethyl, tBu-t-butyl, Bn = benzyl, Ph = phenyl).
Scheme 4
Scheme 4. C5-annulation and C3-olefination of indole derivatives with different acrylates and various alkenes a,b. aReaction conditions: 1 (1.0 equiv.), 2 (5.0 equiv.), [RuCl2(p-cymene)]2 (10 mol%), Cu(OAc)2·H2O (1.5 equiv.), KOAc (0.5 equiv.), n-BuOH (0.2 M), 120 °C, 24 h. bIsolated yields; (Me = methyl, Et = ethyl, tBu-t-butyl, Bn = benzyl, Ph = phenyl).
Scheme 5
Scheme 5. Synthetic transformations of C5-annulated indole derivatives.
Scheme 6
Scheme 6. Mechanistic studies of site-selectivity of the ruthenium-catalysed C–H functionalization.
Scheme 7
Scheme 7. Plausible mechanism.

Similar articles

  • Prescription of Controlled Substances: Benefits and Risks.
    Preuss CV, Kalava A, King KC. Preuss CV, et al. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
  • Anterior Approach Total Ankle Arthroplasty with Patient-Specific Cut Guides.
    Willegger M, Penner MJ, Anderson L, Gagné O, Younger A, Veljkovic A. Willegger M, et al. JBJS Essent Surg Tech. 2025 Aug 15;15(3):e23.00027. doi: 10.2106/JBJS.ST.23.00027. eCollection 2025 Jul-Sep. JBJS Essent Surg Tech. 2025. PMID: 40821726 Free PMC article.
  • Sexual Harassment and Prevention Training.
    Cedeno R, Bohlen J. Cedeno R, et al. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
  • Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Domen J, Tans A, Janssens S, Wickramasinghe D, Lannoy V, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Struyf T, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
  • Sertindole for schizophrenia.
    Lewis R, Bagnall AM, Leitner M. Lewis R, et al. Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.

References

    1. Mason C. P. Edwards K. R. Carlson R. E. Pignatello J. Gleason F. K. Wood J. M. Science. 1982;215:400–402. - PubMed
    1. Richter S. Palumbo M. Mini Rev. Med. Chem. 2003;3:37–49. - PubMed
    1. Pearce A. N. Chia E. W. Berridge M. V. Clark G. R. Harper J. L. Larsen L. Maas E. W. Page M. J. Perry N. B. Webb V. L. et al. . J. Nat. Prod. 2007;70:936–940. - PubMed
    1. Beck J. J. Chou S. C. J. Nat. Prod. 2007;70:891–900. - PubMed
    1. Trani A. Dallanoce C. Panzone G. Ripamonti F. Goldstein B. P. Ciabatti R. J. Med. Chem. 1997;40:967–971. - PubMed

LinkOut - more resources